

Medications, Substances, and Trauma Processing

A clinician's evidence guide

Trauma Essentials | Updated October 2026

Assess participation; coordinate medication decisions with the prescriber. Track sedation, intoxication, attention, memory continuity, and session engagement. When reading a study, note whether the researchers controlled dose, timing, and memory reactivation. Those experimental conditions differ from ordinary psychotherapy.

What the science can—and cannot—tell us

Memory reconsolidation is well supported in animal research and in selected human laboratory paradigms. Translation to complex autobiographical trauma memories and ordinary psychotherapy remains incomplete. Retrieval does not automatically destabilize a memory; boundary conditions include prediction error, memory strength and age, timing, and the specific experimental procedure. No office-based test can confirm that reconsolidation occurred in a particular session.

Clinical outcome data and laboratory mechanism data answer different questions. A rat fear-conditioning experiment can identify a possible biological mechanism; it does not test the effects of a prescribed medication during EMDR, DBR, exposure therapy, or another trauma treatment.

Read the evidence in the right order

1. **Direct human clinical evidence** can tell us whether people receiving a treatment improved and what adverse effects occurred. It still may not identify the mechanism.
2. **Human laboratory evidence** can test tightly controlled fear-learning procedures. A conditioned stimulus is not the same thing as a complex autobiographical trauma memory.
3. **Animal research** can identify candidate circuits, receptors, and timing effects. Translation to human psychotherapy requires another evidentiary step.
4. **Reviews and mechanism papers** synthesize findings or propose explanations; they are not direct medication trials during ordinary psychotherapy.

What to assess around a session

Before: Record medication or substance, dose if known, timing, recent changes, sleep, withdrawal risk, and the prescriber's instructions. Ask what the client notices.

During: Track alertness, orientation, attention, memory continuity, blood-pressure symptoms, intoxication, dissociation, consent, and capacity to stay within workable activation. If the client cannot participate safely, stop and reassess. That decision does not require a reconsolidation theory.

After: Ask what the client remembers, what changed, what returned, and whether adverse effects appeared. Document patterns across sessions before attributing difficulty to any one factor.

Evidence by medication or substance

Medication or substance	What the cited evidence studied	Reasonable clinical conclusion
Benzodiazepines Alprazolam, lorazepam, diazepam, clonazepam	Guina et al. (2015) reviewed 18 clinical and observational studies involving 5,236 participants and concluded that benzodiazepines are ineffective for PTSD treatment and prevention; the review also reported associations with worse psychotherapy outcomes. Makkar et al. (2010) reviewed GABAergic findings from fear-learning studies. These sources do not prove that a prescribed dose blocks reconsolidation during a specific therapy session.	Assess sedation, attention, new-memory problems, falls, dependence risk, and the client's ability to participate. Coordinate medication concerns with the prescriber.
Propranolol Beta-blocker studied in reactivation protocols	Kindt et al. (2009) paired propranolol with memory reactivation in a controlled human fear-conditioning experiment. Clinical reconsolidation studies use planned dosing and timing. Astill Wright et al. (2021) found emerging but heterogeneous PTSD evidence with substantial bias and very low certainty for the pooled treatment outcome.	Interpret propranolol findings within the dose and timing of the studied protocol. Assess participation and treatment response. Medication changes belong with the prescriber.
Clonidine Alpha-2 agonist	Gamache et al. (2012) administered clonidine after retrieval in rat auditory fear conditioning. The study demonstrated a preclinical reconsolidation effect under controlled conditions; it did not study human PTSD psychotherapy.	Assess sedation, dizziness, blood pressure effects, and session participation. Effects on human trauma psychotherapy have not been directly studied.
Prazosin	Do Monte et al. (2013) studied prazosin in a rat olfactory fear-conditioning model. Otis et al. (2015) reviewed noradrenergic mechanisms. Neither source tested prazosin during human trauma psychotherapy.	Assess nightmare response, sleep, dizziness or other adverse effects, and engagement in sessions. Coordinate medication concerns with the prescriber.
Cannabis / THC	Wise et al. (2009) studied acute THC-related working-memory impairment in male rats using a radial-arm maze. It was not a reconsolidation or psychotherapy study. Human effects vary with dose, formulation, tolerance, and timing.	Assess acute intoxication, attention, memory, anxiety, dissociation, and capacity to participate safely. Direct evidence about trauma therapy outcomes remains limited.
Alcohol	White (2003) reviewed alcohol-related disruption of new memory formation and blackouts, especially when blood alcohol rises rapidly. The paper did not test trauma-memory reconsolidation or psychotherapy.	When a client is intoxicated, postpone trauma processing until safety, consent, attention, and memory can be assessed reliably.

Coordinating with prescribers

When sedation, dizziness, memory gaps, or other medication effects appear to affect a session, document what occurred and when. Share that pattern with the prescriber, including dose and timing if known. The prescriber handles medication decisions; the therapist tracks safety, participation, and treatment response.

Bottom line

Medication status is one clinical variable, not a verdict on whether treatment can work. Monitor the client's participation and outcomes. Distinguish direct human clinical evidence from laboratory-conditioned-fear and animal findings. Collaborate with prescribers when medication effects matter.

Verified references

1. Astill Wright, L., Horstmann, L., Holmes, E. A., & Bisson, J. I. (2021). Consolidation/reconsolidation therapies for the prevention and treatment of PTSD and re-experiencing: A systematic review and meta-analysis. *Translational Psychiatry*, 11, 453. <https://doi.org/10.1038/s41398-021-01570-w>
2. Do Monte, F. H. M., Souza, R. R., Wong, T. T., Carobrez, A. P., & De Oliveira, I. R. (2013). Systemic or intra-prelimbic cortex infusion of prazosin impairs fear memory reconsolidation. *Behavioural Brain Research*, 244, 137–141. <https://doi.org/10.1016/j.bbr.2013.01.031>
3. Gamache, K., Pitman, R. K., & Nader, K. (2012). Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder. *Neuropsychopharmacology*, 37(13), 2789–2796. <https://doi.org/10.1038/npp.2012.145>
4. Guina, J., Rossetter, S. R., DeRhodes, B. J., Nahhas, R. W., & Welton, R. S. (2015). Benzodiazepines for PTSD: A systematic review and meta-analysis. *Journal of Psychiatric Practice*, 21(4), 281–303. <https://doi.org/10.1097/PRA.0000000000000091>
5. Kindt, M., Soeter, M., & Vervliet, B. (2009). Beyond extinction: Erasing human fear responses and preventing the return of fear. *Nature Neuroscience*, 12(3), 256–258. <https://doi.org/10.1038/nn.2271>
6. Makkar, S. R., Zhang, S. Q., & Cranney, J. (2010). Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. *Neuropsychopharmacology*, 35(8), 1625–1652. <https://doi.org/10.1038/npp.2010.53>
7. Otis, J. M., Werner, C. T., & Mueller, D. (2015). Noradrenergic regulation of fear and drug-associated memory reconsolidation. *Neuropsychopharmacology*, 40(4), 793–803. <https://doi.org/10.1038/npp.2014.243>
8. White, A. M. (2003). What happened? Alcohol, memory blackouts, and the brain. *Alcohol Research & Health*, 27(2), 186–196. <https://pubmed.ncbi.nlm.nih.gov/articles/PMC6668891/>
9. Wise, L. E., Thorpe, A. J., & Lichtman, A. H. (2009). Hippocampal CB1 receptors mediate the memory impairing effects of Δ^9 -tetrahydrocannabinol. *Neuropsychopharmacology*, 34(9), 2072–2080. <https://doi.org/10.1038/npp.2009.31>

Educational material for licensed clinicians. This document does not provide prescribing advice and is not a substitute for individualized medical care.